Publications
Drug Discovery Core
1. Shim, J. S., Chong, C. R., Bhat, S., Nacev, B. A., Xu, J., Bhang, H., Dhara, S., Han, K. C., Pomper, M. G., Liu, J. O. (2009). Identification of nitroxoline as an inhibitor of methionine aminopeptidase 2 and angiogenesis. Submitted.
2. Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C. V., Liu, J. O., Semenza, G. L. (2008) Inaugural Article: Digoxin and other cardiac glycosides inhibit HIF-1? synthesis and block tumor growth. Proc. Natl. Acad. Sci. USA, 105, 19579-19586. Download PDF
3. Lee, K., Qian, D. Z., Rey, S., Wei, H., Liu, J. O., Semenza, G. L. (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. USA, 106, 2353-2358.
4. Ren, Y. R., Pan, F., Parvez, S., Fleig, A., Chong, C.R., Xu, J., Dang, Y., Zhang, J., Jiang, H., Penner, R., Liu, J. (2008) Clofazimine inhibits human Kv1.3 potassium channel and perturbs calcium oscillation frequency in T lymphocytes. PLoS ONE, 3, e4009. Download PDF
5. Zhang, Y., Byun, Y., Ren, Y.R., Liu, J. O., Leterra, J., Pomper, M. G. (2009) Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. Cancer Res. 2009 Jul 15;69(14):5867-75. Download PDF
Drug Screening Core
1. Ryu B, Kim DS, Deluca AM, Alani RM. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE. 2007 Jul 4;2(7):e594. Download PDF
2. Ryu B, Kim DS, DeLuca AM, Healey MA, Dunlap S, Fackler MJ, Herman J, Alani RM. Id1 expression is transcriptionally regulated in radial growth phase melanomas. Int J Cancer. 2007 Oct 15;121(8):1705-9. Download PDF
3. Hans Hammers, Silvia Paesante, Li Shen, Michelle Rudek, Roberto Pili. Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model. AACR Annual meeting 2008.
4. Hans J. Hammers, Brenda Salumbides, Li Shen, Silvia Paesante, Michelle Rudek, Henk M. Verheul, Roberto Pili. From bedside to the bench: tumor microenvironment is responsible for the acquired resistance to tyrosine kinase inhibitors in renal cell carcinoma. AACR Annual meeting 2008.
5. DeLuca AM, Srinivas A, Alani RM. BRAF kinase in melanoma development and progression. Expert Rev Mol Med. 2008 Feb 18;10:e6. Review.
6. Cummings SD, Ryu B, Samuels MA, Yu X, Meeker AK, Healey MA, Alani RM. Id1 delays senescence of primary human melanocytes. Mol Carcinog. 2008 Sep;47(9):653- 9. Download PDF
7. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Digoxin and other cardiac glycosides inhibit HIF- 1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-86. Epub 2008 Nov 19. Download PDF
8. Li J, Jameson MB, Baguley BC, Pili R, Baker SD. Population pharmacokineticpharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4- acetic acid in cancer patients. Clin Cancer Res. 2008 Apr 1;14(7):2102-10. Download PDF
9. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN, Rudin CM. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008 Apr 1;68(7):2321-8. Download PDF
10. Orita H, Coulter J, Tully E, Kuhajda FP, Gabrielson E. Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin Cancer Res. 2008 Apr 15;14(8):2458-64. Download PDF
11. Jiang T, Collins BJ, Jin N, Watkins DN, Brock MV, Matsui W, Nelkin BD, Ball DW. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res. 2009 Feb 1;69(3):845-54. Download PDF
12. Larson AR, Konat E, Alani RM. Melanoma biomarkers: current status and vision for the future. Nat Clin Pract Oncol. 2009 Feb;6(2):105-17. Download PDF
13. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Dorsch M, Parmigani G, Peacock CD and Watkins DN. A primary xenograft model of small cell lung cancer reveals irreversible changes in gene expression imposed by culture in-vitro. Cancer Research, 2009; 69(8): In Press. Download PDF
14. Stine, M.J., Wang, C.J., Moriarty, W.F., Ryu, B., Cheong, R., Westra, W.H., Levchenko, A., and R.M. Alani. Neuropilin-2 is a mediator of melanoma-endothelial cell communication and melanoma cell proliferation. PNAS, under revision.
Clinical Core
1. Hann CL, Rudin CM. Fast, hungry and unstable: finding the Achilles heel of small-cell lung cancer. Trends Mol Medicine. 2007; 13:150-7. Download PDF
2. Rudin CM, Hann CL, Peacock C, Watkins DN. Novel therapeutic approaches to small cell lung cancer. J Natl Compr Canc Netw. 2008; 6:315-22.
3. Hann CL, Daniel VC, Hierman J, Sugar E, Cope L, Lin M, Watkins DN, Rudin CM. Therapeutic efficacy of ABT-737, a selective inhibitor of Bcl-2, in small cell lung cancer. Cancer Res. 2008; 68:2321-8. Download PDF
4. Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology. 2008; 22:1486-92.
5. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Dorsch M, Parmigiani G, Peacock C, Watkins DN. A primary xenograft model of small cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009; (in press).
Dissemination and Translation of Evidence Core
1. Thun M,Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D, Flanders WD, Jee SH, Katanoda K, Kolonel LN, Lee IM, Marugame T, Palmer JR, Riboli E, Sobue T, Avila-Tang E, Wilkens LR, Samet JM. Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies. PLoS Medicine 2008:5(9) e185:0001-0015. Download PDF
